PatentVest released an analysis of 1,200+ patent documents across 50 oral small-molecule GLP-1 programs, revealing dramatic disparities in patent defensibility among competitors. With injectable GLP-1s reaching only 5% of eligible patients and clinical efficacy converging around 12-16% weight loss, long-term market dominance will depend on patent portfolio strength rather than clinical performance alone. Major patent cliffs for semaglutide (2031) and tirzepatide (2036) will determine which assets become franchises versus facing generic competition.

The global Advanced Drug Delivery Systems market is projected to grow from $299.6 billion in 2025 to $487.4 billion by 2030 at a CAGR of 10.2%. Growth is driven by increasing chronic disease prevalence, nanotechnology advances, and R&D investments. Oncology leads adoption, with North America dominating market share while Asia-Pacific shows the fastest growth. Key innovations include strategic partnerships in antibody-drug conjugates and AI-powered drug development optimization.

Gilead Sciences agreed to acquire Arcellx for $7.8 billion, or $115 per share in cash, plus a $5-per-share contingent value right. The acquisition strengthens Gilead's oncology portfolio by adding anito-cel, a CAR T-cell therapy for multiple myeloma with promising clinical results. Arcellx shares rose on the news and are trading near their 52-week highs.

Gilead Sciences announced a definitive agreement to acquire biotechnology company Arcellx for approximately $7.8 billion ($115 per share in cash), representing a 68% premium to Arcellx's 30-day volume-weighted average price. The deal includes a contingent value right of $5 per share if anito-cel, Arcellx's lead CAR-T therapy, reaches $6 billion in cumulative global net sales by end of 2029. The acquisition is expected to close in Q2 2026 and expands Gilead's existing collaboration with Arcellx on the investigational BCMA-directed CAR-T cell therapy for multiple myeloma.

Gilead Sciences announced the acquisition of Arcellx for $115 per share in cash plus a $5 per share contingent value right, totaling $7.8 billion in implied equity value. The deal aims to accelerate development and commercialization of anito-cel, a CAR T-cell therapy for relapsed or refractory multiple myeloma, with FDA approval anticipated by December 2026. The transaction is expected to be accretive to Gilead's earnings per share starting in 2028.

Xilio Therapeutics announced the pricing of an underwritten offering of 74.78 million pre-funded warrants at $0.5349 per warrant, expected to raise approximately $40 million in gross proceeds. The financing was led by existing investor Coastlands Capital and included participation from Gilead Sciences, OrbiMed, and Perceptive Advisors. Proceeds will be used to advance product development and for general corporate purposes.

Software stocks declined sharply with the iShares Tech-Expanded Software Sector ETF (IGV) falling over 3%, while major U.S. indexes posted modest gains. The January jobs report showed strong headline numbers but disappointing revisions, with 2025 job growth at its weakest since 2003. Bitcoin dropped over 3% to $66,000, and notable losers included Unity Software, Mattel, and Zillow, while semiconductors and energy stocks outperformed.

The global Hepatitis B treatment market is valued at USD 4.52 billion in 2025 and is projected to reach USD 7.74 billion by 2033, growing at a CAGR of 6.97%. Growth is driven by expanded screening programs, increased antiviral therapy adoption, and novel treatment innovations. The U.S. market is expected to grow from USD 1.00 billion to USD 1.54 billion by 2033.

The global targeted cancer therapy market is projected to grow from USD 90.89 billion in 2025 to USD 175.48 billion by 2035 at a CAGR of 6.80%. Growth is driven by antibody-drug conjugates (ADCs), KRAS inhibitors, bispecific antibodies, and regulatory productivity. Monoclonal antibodies capture 43% revenue share, lung cancer represents 32% of the market, and hospitals account for 58% of end-user share. North America dominates with 39% market share.

The article argues that the Magnificent 7 tech stocks' dominance is fading as AI benefits spread to other sectors. The author recommends rebalancing away from tech and investing in the Abrdn Life Sciences Investors (HQL) closed-end fund, which yields 11.6% and focuses on biopharma companies poised to benefit from AI optimization in drug development.

The U.S. Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program, marking the first time the initiative includes drugs reimbursed under Medicare Part B. Negotiations will take place in 2026, with prices taking effect January 1, 2028. The second cycle negotiations are estimated to save Medicare $8.5 billion (36% reduction) if prices had been in place in 2024.

The global autologous cell therapy market, valued at $10.12 billion in 2024, is projected to grow to $44.55 billion by 2033 at a CAGR of 17.90%. Growth is driven by rising demand for personalized, patient-derived treatments for chronic diseases including cancer, cardiovascular disorders, and neurodegenerative conditions. North America leads the market with over 44% share, supported by a robust clinical trial ecosystem and regulatory frameworks like the FDA's RMAT designation.